Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695057 | 0.86 | POLB (0.33) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL12906309 | 0.83 | CDK8 (0.42) | LMNATP53CDK8ACVR1ALDH1A1 | |
| SCHEMBL20695034 | 0.76 | MAOB (0.49) | LMNATSHRNPBWR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL469902 | 0.73 | CRHR1 (0.34) | MAPTLMNATP53POLBCDK8 | |
| SCHEMBL513319 | 0.71 | NMT1 (0.36) | LMNAKMT2ACDK8ACVR1NPBWR1 | |
| SCHEMBL469899 | 0.71 | GSK3B (0.46) | KMT2AMEN1TSHRPOLBALDH1A1 | |
| SCHEMBL20695068 | 0.71 | L3MBTL1 (0.39) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15935630 | 0.70 | NPC1 (0.45) | KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15353202 | 0.70 | SIRT2 (0.46) | MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL469883 | 0.70 | NPC1 (0.35) | LMNATSHRPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | PLPBP, PNPO, PIR | ESRRA 4692/4885MAPT 3453/4885LMNA 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.